Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia.
Am J Kidney Dis. 2010 Jan;55(1):121-31. doi: 10.1053/j.ajkd.2009.08.020. Epub 2009 Nov 22.
The study aim was to examine the frequency, predictors, treatment, and clinical outcomes of peritoneal dialysis-associated polymicrobial peritonitis.
Observational cohort study using ANZDATA (The Australia and New Zealand Dialysis and Transplant Registry) data.
SETTING & PARTICIPANTS: All Australian peritoneal dialysis patients between October 2003 and December 2006.
Age, sex, race, body mass index, baseline renal function, late referral, kidney disease, smoking status, comorbidity, peritoneal permeability, center, state, organisms, and antibiotic regimen.
OUTCOMES & MEASUREMENTS: Polymicrobial peritonitis occurrence, relapse, hospitalization, catheter removal, hemodialysis transfer, and death.
359 episodes of polymicrobial peritonitis occurred in 324 individuals, representing 10% of all peritonitis episodes during 6,002 patient-years. The organisms isolated included mixed Gram-positive and Gram-negative organisms (41%), pure Gram-negative organisms (22%), pure Gram-positive organisms (25%), and mixed bacteria and fungi (13%). There were no significant independent predictors of polymicrobial peritonitis except for the presence of chronic lung disease. Compared with single-organism infections, polymicrobial peritonitis was associated with higher rates of hospitalization (83% vs 68%; P < 0.001), catheter removal (43% vs 19%; P < 0.001), permanent hemodialysis transfer (38% vs 15%; P < 0.001), and death (4% vs 2%; P = 0.03). Isolation of fungus or Gram-negative bacteria was the primary predictor of adverse clinical outcomes. Pure Gram-positive peritonitis had the best clinical outcomes. Patients who had their catheters removed >1 week after polymicrobial peritonitis onset were significantly more likely to be permanently transferred to hemodialysis therapy than those who had earlier catheter removal (92% vs 81%; P = 0.05).
Limited covariate adjustment. Residual confounding and coding bias could not be excluded.
Polymicrobial peritonitis can be treated successfully using antibiotics alone without catheter removal in most cases, particularly when only Gram-positive organisms are isolated. Isolation of Gram-negative bacteria (with or without Gram-positive bacteria) or fungi carries a worse prognosis and generally should be treated with early catheter removal and appropriate antimicrobial therapy.
本研究旨在探讨腹膜透析相关性多微生物性腹膜炎的发生频率、预测因素、治疗方法和临床转归。
使用 ANZDATA(澳大利亚和新西兰透析和移植登记处)数据进行观察性队列研究。
2003 年 10 月至 2006 年 12 月期间所有澳大利亚腹膜透析患者。
年龄、性别、种族、体重指数、基线肾功能、晚期转归、肾脏疾病、吸烟状况、合并症、腹膜通透性、中心、州、微生物和抗生素方案。
多微生物性腹膜炎的发生、复发、住院、导管拔除、血液透析转归和死亡。
324 例患者发生 359 例次多微生物性腹膜炎,占 6002 患者年中所有腹膜炎病例的 10%。分离的微生物包括混合革兰阳性和革兰阴性菌(41%)、单纯革兰阴性菌(22%)、单纯革兰阳性菌(25%)和混合细菌和真菌(13%)。除慢性肺部疾病外,多微生物性腹膜炎无明显独立预测因素。与单微生物感染相比,多微生物性腹膜炎的住院率(83% vs. 68%;P < 0.001)、导管拔除率(43% vs. 19%;P < 0.001)、永久性血液透析转归率(38% vs. 15%;P < 0.001)和死亡率(4% vs. 2%;P = 0.03)更高。真菌或革兰阴性菌的分离是不良临床结局的主要预测因素。单纯革兰阳性腹膜炎的临床结局最好。多微生物性腹膜炎发病后 1 周以上拔除导管的患者永久性转归为血液透析治疗的可能性显著高于导管拔除较早的患者(92% vs. 81%;P = 0.05)。
有限的协变量调整。残留混杂和编码偏倚不能排除。
在大多数情况下,多微生物性腹膜炎可单独使用抗生素成功治疗,而无需拔除导管,尤其是仅分离出革兰阳性菌时。分离出革兰阴性菌(伴有或不伴有革兰阳性菌)或真菌预示着更差的预后,通常应采用早期导管拔除和适当的抗菌治疗。